Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Breast Cancer Res. 2009;11(1):202. doi: 10.1186/bcr2224. Epub 2009 Feb 26.

Transforming growth factor-beta in breast cancer: too much, too late.

Author information

  • 1New York University Langone School of Medicine, New York, NY 10016, USA. mhbarcellos-hoff@nyumc.org

Abstract

The contribution of transforming growth factor (TGF)beta to breast cancer has been studied from a myriad perspectives since seminal studies more than two decades ago. Although the action of TGFbeta as a canonical tumor suppressor in breast is without a doubt, there is compelling evidence that TGFbeta is frequently subverted in a malignant plexus that drives breast cancer. New knowledge that TGFbeta regulates the DNA damage response, which underlies cancer therapy, reveals another facet of TGFbeta biology that impedes cancer control. Too much TGFbeta, too late in cancer progression is the fundamental motivation for pharmaceutical inhibition.

PMID:
19291273
[PubMed - indexed for MEDLINE]
PMCID:
PMC2687712
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Write to the Help Desk